FDA’s controversial approval of Alzheimer’s drug draws calls for reform
Boston area experts say it spotlights systemic flaws in the health care system
By 
WHEN MASS GENERAL BRIGHAM announced two weeks ago that it would not offer a controversial new drug treatment for Alzheimer’s disease to patients, it was an important statement from the state’s leading provider network. On Thursday, Blue Cross Blue Shield of Massachusetts, the state’s largest private insurer, said it won’t cover the drug developed by(...)